Literature DB >> 9356807

Progressive vaccinia treated with ribavirin and vaccinia immune globulin.

A M Kesson1, J K Ferguson, W D Rawlinson, A L Cunningham.   

Abstract

A 67-year-old man with metastatic melanoma and chronic lymphocytic leukemia was inadvertently given a vaccinia melanoma oncolysate vaccination. He developed progressive vaccinia at the site of inoculation. The lesion started to heal only when he was treated with ribavirin. Vaccinia immune globulin was administered and appeared to help control the initial lesion and limit the development of satellite lesions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9356807     DOI: 10.1086/515534

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

Review 1.  Passive immunity in prevention and treatment of infectious diseases.

Authors:  M A Keller; E R Stiehm
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.

Authors:  Donald F Smee; Robert W Sidwell; Debbie Kefauver; Mike Bray; John W Huggins
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

3.  Evaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice.

Authors:  E Bart Tarbet; Deanna Larson; Bentley J Anderson; Kevin W Bailey; Min-Hui Wong; Donald F Smee
Journal:  Antiviral Res       Date:  2011-03-23       Impact factor: 5.970

Review 4.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

5.  Effect of 5-iodo-2'-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice.

Authors:  Johan Neyts; Erik Verbeken; Erik De Clercq
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

6.  Therapeutic and prophylactic drugs to treat orthopoxvirus infections.

Authors:  Scott Parker; Lauren Handley; R Mark Buller
Journal:  Future Virol       Date:  2008-11       Impact factor: 1.831

7.  Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.

Authors:  Joseph W Golden; Marina Zaitseva; Senta Kapnick; Robert W Fisher; Malgorzata G Mikolajczyk; John Ballantyne; Hana Golding; Jay W Hooper
Journal:  Virol J       Date:  2011-09-20       Impact factor: 4.099

8.  Detection and discrimination of orthopoxviruses using microarrays of immobilized oligonucleotides.

Authors:  Majid Laassri; Vladimir Chizhikov; Maxim Mikheev; Sergei Shchelkunov; Konstantin Chumakov
Journal:  J Virol Methods       Date:  2003-09       Impact factor: 2.623

9.  Frequency of revaccination against smallpox.

Authors:  Samuel Baron; Jingzhi Pan; Joyce Poast
Journal:  Emerg Infect Dis       Date:  2003-11       Impact factor: 6.883

Review 10.  Cidofovir in the treatment of poxvirus infections.

Authors:  Erik De Clercq
Journal:  Antiviral Res       Date:  2002-07       Impact factor: 10.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.